CN118159259A - 用于治疗癌症的因多昔芬 - Google Patents

用于治疗癌症的因多昔芬 Download PDF

Info

Publication number
CN118159259A
CN118159259A CN202280071316.2A CN202280071316A CN118159259A CN 118159259 A CN118159259 A CN 118159259A CN 202280071316 A CN202280071316 A CN 202280071316A CN 118159259 A CN118159259 A CN 118159259A
Authority
CN
China
Prior art keywords
cancer
clomefene
doxifene
subject
response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280071316.2A
Other languages
English (en)
Chinese (zh)
Inventor
史蒂文·C·夸伊
卡拉·格兰多里
卡塔尼亚·卡佩利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atosa Therapeutics
Original Assignee
Atosa Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atosa Therapeutics filed Critical Atosa Therapeutics
Publication of CN118159259A publication Critical patent/CN118159259A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280071316.2A 2021-10-28 2022-10-27 用于治疗癌症的因多昔芬 Pending CN118159259A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163272869P 2021-10-28 2021-10-28
US63/272,869 2021-10-28
PCT/US2022/048061 WO2023076496A1 (en) 2021-10-28 2022-10-27 Endoxifen for treatment of cancers

Publications (1)

Publication Number Publication Date
CN118159259A true CN118159259A (zh) 2024-06-07

Family

ID=86158538

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280071316.2A Pending CN118159259A (zh) 2021-10-28 2022-10-27 用于治疗癌症的因多昔芬

Country Status (10)

Country Link
US (1) US20250041245A1 (enExample)
EP (1) EP4422608A4 (enExample)
JP (1) JP2024541900A (enExample)
KR (1) KR20240093500A (enExample)
CN (1) CN118159259A (enExample)
AU (1) AU2022378576A1 (enExample)
CA (1) CA3232972A1 (enExample)
IL (1) IL312037A (enExample)
MX (1) MX2024005220A (enExample)
WO (1) WO2023076496A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022232924A1 (en) * 2021-03-11 2023-07-06 Atossa Therapeutics, Inc. Endoxifen for treatment of ovarian cancer
CN117338780A (zh) * 2023-09-21 2024-01-05 中国人民解放军海军军医大学 帕罗西汀在制备抗肿瘤药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013033430A1 (en) * 2011-09-02 2013-03-07 Wake Forest School Of Medicine Targeted delivery and prodrug designs for platinum-acridine anti-cancer compounds and methods thereof
EP2773340B1 (en) * 2011-11-04 2020-01-08 Myron R. Szewczuk Use of neu1 sialidase inhibitors in the treatment of cancer
DE102015222031A1 (de) * 2015-11-10 2017-05-11 Robert Bosch Gesellschaft Für Medizinische Forschung Mbh Synthese von (Z)-Endoxifenhydrochlorid
WO2017127442A1 (en) * 2016-01-18 2017-07-27 The Regents Of The University Of California Methods for treating cancer with rorgamma inhibitors
JP7662204B2 (ja) * 2019-07-03 2025-04-15 アトッサ・セラピューティクス・インコーポレイテッド エンドキシフェンの徐放性組成物
CN115087466A (zh) * 2019-12-12 2022-09-20 森迪生物科学公司 用于细胞的调控装甲的方法和组合物
AU2022232924A1 (en) * 2021-03-11 2023-07-06 Atossa Therapeutics, Inc. Endoxifen for treatment of ovarian cancer
CN119300811A (zh) * 2022-04-26 2025-01-10 阿托萨治疗学公司 高剂量因多昔芬制剂和使用方法

Also Published As

Publication number Publication date
WO2023076496A1 (en) 2023-05-04
EP4422608A4 (en) 2025-09-24
US20250041245A1 (en) 2025-02-06
EP4422608A1 (en) 2024-09-04
CA3232972A1 (en) 2023-05-04
JP2024541900A (ja) 2024-11-13
MX2024005220A (es) 2024-05-16
KR20240093500A (ko) 2024-06-24
IL312037A (en) 2024-06-01
AU2022378576A1 (en) 2024-03-28

Similar Documents

Publication Publication Date Title
US12281056B2 (en) Methods for making and using endoxifen
JP2021008475A (ja) Ｈｅｒ２増幅性癌の処置のための方法
JP6620338B2 (ja) 低用量ナルトレキソンによるがん細胞の準備刺激
US20250041245A1 (en) Endoxifen for treatment of cancers
CN115175899A (zh) 使用cdk12/13抑制剂治疗癌症
JP2021105005A (ja) 癌治療
AU2026200456A1 (en) Treatment of canine cancers
AU2012316266A1 (en) Combination therapy for chemoresistant cancers
US20240156752A1 (en) Endoxifen for treatment of ovarian cancer
CN117377472A (zh) 使用包括gdc-9545和gdc-0077的组合疗法治疗乳腺癌
CN121568688A (zh) 因多昔芬组合物及其使用方法及其合成
HK40105626A (zh) 用於治疗癌症的因多昔芬
Chen et al. Targeted Cancer Therapies, from Small Molecules to Antibodies
KR20160086962A (ko) 삼중 음성 유방 암 치료를 위해 카보플라틴과 병용된 벨리파리브
WO2026101937A1 (en) Compositions comprising (z)-endoxifen and a cdk4/6 inhibitor and methods of use thereof
WO2025151443A1 (en) Endoxifen for treatment of rare cancers
US20250170096A1 (en) Oxphos inhibitors for use in treating cancer
HK40031003A (en) Methods for making and using endoxifen
JP2023547108A (ja) γサブユニットを標的とするミトコンドリアＡＴＰ阻害剤は転移を予防する
WO2009142968A2 (en) Valproic acid salts

Legal Events

Date Code Title Description
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40105626

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination